1
week
Adaptive COVID-19 Treatment Trial (ACTT)
Drug
Placebo; Remdesivir
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Condition
COVID-19
Status
Completed | PHASE3 | May 21, 2020
1 total | 1 suggested
Top This Week
Vote
0
week
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Drug
Baxdrostat; Placebo
Sponsor
AstraZeneca
Condition
Uncontrolled Hypertension; Resistant Hypertension
Status
Active Not Recruiting | PHASE3 | Nov 24, 2025
0 total | 1 suggested
0
week
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Drug
BEAM-302
Sponsor
Beam Therapeutics Inc.
Condition
Alpha 1-Antitrypsin Deficiency
Status
Recruiting | PHASE1; PHASE2 | May 2028
0 total | 1 suggested
0
week
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Drug
Psilocybin
Sponsor
COMPASS Pathways
Condition
Major Depressive Disorder
Status
Active Not Recruiting | PHASE2 | Sep 2025
0 total | 1 suggested
0
week
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Drug
EDG-7500
Sponsor
Edgewise Therapeutics, Inc.
Condition
Hypertrophic Cardiomyopathy
Status
Active Not Recruiting | PHASE2 | Jun 2026
0 total | 1 suggested
0
week
A Study of Brenipatide in Participants With Opioid Use Disorder
Drug
Brenipatide; Placebo; Buprenorphine
Sponsor
Eli Lilly and Company
Condition
Opioid Use Disorder
Status
Recruiting | PHASE2 | Aug 2027
0 total | 1 suggested
0
week
A Study of Brenipatide in Participants With Alcohol Use Disorder
Drug
LY3537031; Placebo
Sponsor
Eli Lilly and Company
Condition
Alcohol Use Disorder
Status
Recruiting | PHASE3 | Apr 2028
0 total | 1 suggested
0
week
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Drug
NTLA-2002; Normal Saline IV Administration
Sponsor
Intellia Therapeutics
Condition
Hereditary Angioedema
Status
Active Not Recruiting | PHASE3 | Apr 2026
0 total | 1 suggested
0
week
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Drug
Intismeran autogene; Pembrolizumab; Placebo
Sponsor
Merck Sharp & Dohme LLC
Condition
Melanoma
Status
Active Not Recruiting | PHASE3 | Oct 26, 2029
0 total | 1 suggested